KR100847222B1 - Phase transition cosmetic transdermal delivery system with increased skin absorption - Google Patents

Abstract

The present invention relates to a skin cosmetic patch for effectively delivering an effective substance exhibiting the effects of skin whitening, slimming, wrinkle improvement, wrinkle increase inhibition, anti-aging, atopic improvement, etc., which is liquefied by a back layer, an adhesive layer, body temperature or friction. Or includes a drug layer and a release liner; Or the skin cosmetic patch of the present invention comprising a backing layer, a drug-adhesive composite layer liquefied by body temperature or friction, and a release liner, the drug-containing drug layer or the drug-adhesive composite layer containing the drug is solid before attachment but not after body attachment. Alternatively, the liquid is liquefied by friction, and thus the permeability to the skin is high, so that the rapid absorption of the drug and the rapid effect expression can be achieved and it is convenient to use.

Phase change, skin beauty patch, whitening, slimming, wrinkle improvement, anti aging, atopic improvement.

Description

Phase change skin cosmetic patch with increased absorption rate {PHASE TRANSITION COSMETIC TRANSDERMAL DELIVERY SYSTEM WITH INCREASED SKIN ABSORPTION}

1 is a schematic side cross-sectional view of a skin care patch according to an embodiment of the present invention,

Figure 2 is a schematic side cross-sectional view of a skin care patch according to another embodiment of the present invention.

The present invention relates to a skin care patch, which is solid before application but changes to a liquid state by body temperature and friction with the skin after application, resulting in skin whitening, slimming, wrinkle improvement, wrinkle increase inhibition, anti-aging, atopic improvement, etc. It relates to patch formulations for effectively delivering an active substance.

Methods for delivering drugs transdermally include membrane controlled systems, adhesive dispersion type systems, matrix diffusion controlled systems, and micro-reservoir systems. It can be divided into four types of dissolution controlled system.

In the membrane controlled system, the drug storage layer is usually surrounded by an impermeable membrane such as aluminum-coated plastic and a polymer membrane (emission control membrane) that controls the permeation rate. It is uniformly distributed in the inside, or is melt | dissolved or suspended in the liquid phase with high viscosity, and is discharged through a release control film | membrane. The emission control membrane may or may not have a fine porous structure with known permeability. The exterior of the release control membrane has a structure that is compatible with the drug and adheres well to the skin using a pressure sensitive adhesive that does not cause hypersensitivity reactions such as skin redness. Products manufactured in this form include Ciba Transderm-Nitro ^® , an angina drug, Transderm-Scop ^® , which is used as an anti-nausea agent, and Catapress-TTS ^® , Boehringer Ingelheim, which is used for high-pressure therapy.

The adhesive dispersion type system is a simplified form of the membrane controlled system mentioned above. Instead of completely enclosing the drug storage layer, the adhesive is dispersed directly in an adhesive such as rubber, acrylic or silicone. The solution is applied to the impermeable support layer in a single layer or multiple layers using a casting or hot melt method. Alternatively, it may be prepared using a thin adhesive film free of drugs having a constant permeability on top of the drug storage layer.

The matrix diffusion controlled system creates a drug storage layer in which the drug is dispersed in a hydrophilic or lipophilic polymer matrix and contains an occlusive base contained in the device of impermeable plastic to prevent diffusion in the opposite direction. It is prepared by attaching to a plate). Unlike the other two systems mentioned previously, the adhesive is not applied to the entire surface, but to the drug matrix on the dispersed matrix edge. Formulations developed in this form include Nitro-Dur ^® from Key.

The micro-reservoir dissolution controlled system type preparation is a complex of membrane controlled system and adhesive dispersion type system. The drug is first suspended in an aqueous solution of a water-soluble polymer, and then the drug suspension is prepared by dispersing fine drug storage layer particles that are not liberated by mechanical force in the fat-soluble polymer. The thermodynamically unstable dispersion system is stabilized by crosslinking polymer chains immediately and is made of a polymer disk having a certain thickness, and is completed by attaching a polymer disk containing such a drug to the center of an adhesive pad. Formulations developed in this form include Searle Nitrodisc ^® for the treatment of angina pectoris.

The conventional transdermal absorption system mentioned above has the advantage that the drug can be released for a long time to maintain an effective blood concentration, and can be used for a drug having a short half-life. However, in these systems, there are many limitations to rapid drug delivery due to delayed absorption of the drug, etc., and there is a disadvantage in that the drug crystallizes on the formulation when a high concentration of drug is used to increase skin absorption efficiency.

In consideration of the problems of the conventional transdermal absorption system as described above, in the present invention, as a preparation to obtain the effect of whitening, slimming, wrinkle improvement, anti-aging, atopic improvement by adhering to the skin, the skin penetration rate of the drug is used quickly It aims to provide this convenient skin care patch.

The skin care patch of the present invention for achieving the above object,

A patch-like preparation for adhering to skin, comprising: a skin cosmetic patch comprising a backing layer, an adhesive layer, a drug layer liquefied by body temperature or friction, and a release liner; or

It is a patch-form preparation which adheres to skin, It is a skin cosmetic patch containing a back layer, the drug adhesive layer liquefied by body temperature or friction, and a release liner.

The present invention relates to a patch formulation for delivering an effective substance that is effective for skin whitening, slimming, wrinkle improvement, anti-aging, atopic dermatitis, etc. It has an adhesive-adhesive composite layer or a drug-adhesive composite layer containing a drug, or an adhesive layer and a drug layer, and includes a removable release liner, in which the drug-containing part is liquefied by body temperature, It is characterized in that the part containing the drug is liquefied using the sol-gel change by friction.

Specifically, the patch formulation of the present invention has the following configuration:

a) drug impermeable backing layer;

b) a drug-adhesive composite layer which is in direct contact with skin to give adhesion and contains a drug therein; And

c) comprises a removable release liner layer, or

a) drug impermeable backing layer;

b-1) an adhesive layer under the back layer;

b-2) a drug layer containing the drug; And

c) a removable release liner layer.

Here, the drug-adhesive composite layer and the drug layer may have a single layer or a structure of two or more layers. The drug layer may be prepared in several layers and the absorption may be promoted by using a concentration gradient of the drug.

The most characteristic part of the layers constituting the patch formulation of the present invention is a drug layer or drug-adhesive composite layer containing a drug, which has a property of liquefying by body temperature or liquefying by friction. In other words, unlike the existing patch formulation, the drug matrix of the drug layer and the drug-adhesive composite layer containing the drug is liquefied by body temperature or friction, so that the permeability to the skin is increased, so that the rapid absorption of the drug and the rapid effect expression are thus achieved. It is possible and convenient to use.

Bases of the drug layer matrix liquefied by body temperature used in the patch formulation of the present invention include suppository bases such as cacao butter, glycerogelatin, Witepsol, laurin paper, cetyl ester wax, fine Waxes such as crystalline waxes, non-emulsifying waxes, white waxes and yellow waxes, and poloxamers having sol-gel changes with temperature , Derivative of poly (N-isopropylacrylamide), derivative of poly (N-cyclopropylmethacrylamide), derivative of poly (N-cyclopropylmethacrylamide), diacetone acrylamide And copolymers of hydroxyethyl acrylate may be used, and these may be used alone or in a mixture. In addition, polyols such as polyethylene glycol and propylene glycol may be added to control the melting point.

It is also possible to use a configuration in which the drug matrix is turned into a liquid by friction. In this case, the absorption of the drug increases because it is liquefied by massage or fine movement after application to the skin. The constituents that can be used include dimethicones, cyclomethicone or copolymers having a basic structure thereof, and dimethicone copolyol crosspolymer dimethicone alone or as a mixture. Polyvinyl alcohol, poloxamer, polyvinyl pyrrolidone, polyvinylpyrrolidone / vinyl acetate copolymer, hydroxypropyl cellulose ), Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropylethyl cellulose, polyox, carboxymethyl cellulose, carboxypropyl cellulose Xanthan gum, a polymer of cellulose and its salts xanthan gum, carrageenan gum, alginate gum, Karayan gum, arabic gum and its salt derivatives, gelatin, polyacrylic acid, carbo Polymers such as carbopol, polyquaternium-11, polyquaternium-39, and polyalkylvinylether-maleic acid copolymers (PVM / MA copolymer) may be added alone or in a mixture. can do.

In addition, an absorption enhancer (enhancer) may be used in the drug matrix to increase the skin permeability of the drug. In this case, absorption accelerators usable may include hydrocarbons such as alkanes and alkenes having 9 to 22 carbon atoms. Alcohols such as ethanol, methanol, lauryl alcohol, polyols such as polyethylene glycol, propylene glycol, lauric acid, myristic acid ), Fatty acids and derivatives such as stearic acid and oleic acid, IPM, glyceryl monolaurate, glyceryl monooleate, glyceryl monocaprylate ), Esters such as ethyloleate, ethyldecanoate, N, N-dimethylamino acetate, 1- (N, N-dimethylamino) -2- F Alkyl amino esters such as ropanol decanoate (1- (N, N-dimethylamino) -2-propanol decanoate), Azone®, dimethylformamide, demethylacetamide Amines such as amides such as amide, PEG2 oleamine, phenethylamine, stearylamine, triethylamine, dodecylamine, and the like Salts, aromatic compounds such as carvacrol, thymol, anethole, sulfoxides such as DMSO, n-decylmethyl sulfoxide, β- Cyclodexrins such as CD and HP-β-CD, terpenes such as α-terpene, p-menthane, d-limonene, dipentene and menthol Terpenes, N-methyl-pyrrolidone; Pyrrolidone and imidazole derivatives such as NMP), 1-ethyl pyrrolidone, and 1-butyl pyrrolidone. Can be.

The content of these absorption accelerators may be used in an amount of 0.001 to 10% based on the total weight of the drug layer, and preferably 0.01 to 5%.

The role of the backing layer is to deliver the drug in one direction towards the skin, to protect the interior (adhesive layer, drug layer) from physical and chemical contact, or to help maintain the shape of the product. . Materials that can be used to demonstrate these properties include polyvinyl acetate, ethyl cellulose, poly methyl methacrylate, methacryloyl ethyl betaine / methacylate copolymer, Yukaformer; Mitsubishi), methacrylic acid copolymers (Eudragit L 100, Eudragit L 125, Eudragit L 100-55, Eudragit L 30D-55), aminoalkyl methacrylate copolymers (Eudragit E 100, Eudragit E 125, Eudragit RL 100, Eudragit RL 30D), cellulose acetate phthalate, polyvinylpyrrolidone / vinyl acetate copolymer, hydroxypropyl cellulose, hydroxypropylmethyl Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl Polymers such as hydroxypropylethyl cellulose, polyethylene terephthalate, polyethylene, polypropylene, polyvinyl chloride, metal foils such as silicone matrix, urethane matrix, rubber, aluminum foil, and fabrics such as polymer-metal compositions and nonwoven fabrics Etc. can be used and these can be used individually or in mixture. In addition, the present invention may also be manufactured by a casting method using a solvent or a hot melt method.

Various plasticizers can be added and used for a back layer. In addition to the above-mentioned plasticizers propylene glycol, glycerine, polyethylene glycol, more plasticizers can be used depending on the solvent used, caster oil, hydrogenated castor oil (hydrogenated caster oil) can also be used.

The adhesive layer may be made of a pressure sensitive adhesive to facilitate adhesion to the skin. At this time, the adhesive may be silicone such as polydimethylsiloxane, acrylic adhesive such as polyacrylate, polyisobutylene-based adhesive or the like.

The release liner layer is removed before adhering to the skin. They are made of a material whose layers easily peel off from neighboring pressure sensitive adhesive layers. The release liner layer may be prepared using a drug impermeable polymer such as polyester coated with a material such as silicone or hydrocarbons with added fluorine. It can also be attached directly into the blister of the packaging.

In the drug layer or drug-adhesive composite layer, a surfactant may be added to enhance the solubility of the drug. Surfactants include anionic surfactants such as docusate sodium, emulsifying wax, self emulsifying glyceryl monooleate, sodium lauryl sulfate, benzyl chloride Cationic surfactants such as tonium (benzethonium chloride), cetrimide and emulsifying wax, butylparaben, propylparaben, ethylparaben, methylparaben and methylparaben Glyceryl monooleate, polyoxyethylene alkyl esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, poly Oxyethylene stearate, polysorbate, sorbic acid, sorbitan ester A non-ionic surfactant acids, such as (sorbitan ester) may be used alone or in combination.

In addition, the drug layer may include the following drugs to exhibit the effects of anti-aging, skin whitening, slimming, wrinkle improvement, atopic dermatitis, etc .:

To improve atopy, lotus root powder, buckwheat powder, onion powder, N-stearoyl-phytosphingosine, Bletilla striata REICHB. Fil., Perilla ocymoides, Echinacea purpurea, Fermented soybean extract, palm cactus extract, panesol, sewage, leaflet, extract of illite, ganoderma lucidum, yugeunpi, licorice, baekbokyeong, Baekjima, baeknyeoncho, dermis, fruit extract, catechin and the like can be used alone or in a mixture. Their content may be in the range of 0.001 to 30% by weight of the drug layer, preferably 0.01 to 10%.

Skin whitening agents include arbutin, kojic acid, selina, vitamin C, phytoclear EL-1, PaSSO3Ca (calcium D-pantetheine-S-sulfonate), Tretinoin, Glutathione, Ascorbic Acid, Soybean Extract, Igusa Extract, Irgo, Algae Extract, Shellfish Extract, Herbal Extract, Mushroom Extract, Myrsinaceae Plant Embelli Extracts of Embelia javanica DC., Extracts from plants of the genus Ran and simbadium, sunflower seed extract, lactic acid, retinoic acid, linoleic acid, glycolic acid Niacinamide, lecithin, neoglycoproteins, LG106W, rucinol, placenta extract, ellagic acid, chamomile extract, t-AMCHA (trans-4- (aminomethyl) cyclohexane carboxyl ic acid), AA-2G (vit-c-glu), 3-ethoxy-vitamin C, mulberry extract, oil-soluble licorice extract, halves, upper extremity, situation extract, kojyl caffeate, vitamin C-PGM, Hydroquinone and the like can be used singly or in mixture. Their content may range from 0.001 to 30% by weight of the drug layer, preferably from 0.01 to 10%.

Ascorbic acid (Vit C), beta-carotene (pro-Vit A), tocopherol (Vit E), isoflavone (genistein), resveratrol Pycnogenol, superoxide dismutase (SOD), catalase, alpha-lipoic acid, selenium, coenzyme Q10, alpha-hydroxy acid acids), rooibos fermented extract, rhizome extract, tannin, lumberjack extract, etc. may be used alone or in a mixture. Their content may range from 0.001 to 30% by weight of the drug layer, preferably from 0.01 to 10%.

Slimming, weight-reducing substances include caffeine, lipoic acid, theophylline, theanine, genistein, L-carnitine, Centella Asia Tica, Ruscus, Fucus, Ivy, Horse Chestnut, Gotu Kola Extract, Flavonoids, Coffee Extract, Cola Extract, Seaweed Extract, Mushroom Extract, Theobromine, Theophylline Acetate, Aminophylline, Uncaria Tomentosa, Catechin, etc. Can be used as Their content may range from 0.001 to 30% by weight of the drug layer, preferably from 0.01 to 10%.

Medications for improving wrinkles include Medimin A, EGCG, angelic complex, paeoniflorin, vitamin C, vitamin E, DPHP, ursolic acid, retinol, polyethoxylation Retinamide, retinyl palmitate, 7-DHC (7-dehydrocholesterol), adenosine, kinetin, betel extract, octasome, betulin, donkey, succinct, celestial organ, tired person, sewage, astragalus, mold , Botanical extracts of licorice, earl pear, ginsenosides, prickly pear extract, bergenin, falconus extract, package, rye root, pagoji, red ginseng extract, camphor ginseng extract, crape myrtle extract, rhubarb extract, parsley extract, betel nut catechu L.) extract, brown rice extract, and root extract may be used alone or as a mixture. Their content may range from 0.001 to 30% by weight of the drug layer, preferably from 0.01 to 10%.

1 is a schematic side cross-sectional view of a skin care patch according to an embodiment of the present invention, Figure 2 is a schematic side cross-sectional view of a skin care patch according to another embodiment of the present invention. 1 shows a patch of the invention consisting of four layers of a backing layer, an adhesive layer, a drug layer, and a release liner, and FIG. 2 is a bone consisting of three layers of a backing layer, a drug / adhesive composite layer, and a release liner. The patch of the invention is shown.

Hereinafter, the present invention will be described in more detail with reference to preferred embodiments of the present invention. However, these examples are only illustrative to aid the understanding of the present invention, and the scope of the present invention is not limited thereto.

Example  One

Skin whitening patches were prepared with the following composition:

(1) drug layer preparation solution

Arbutin 1%

Dimethicone 3.5%

Cyclodimethicone 6%

Polyethylene glycol 3%

Polyvinyl pyrrolidone 4%

Dimethicone Copolyol Crosspolymer Dimethicone 1%

Stearic acid 0.1%

Purified water was added to make 100%.

(2) Adhesive layer manufacturing solution

Silicone 35%

Heptane or ethyl acetate 65%

Arbutin was dissolved in water and then increased by adding polyvinyl pyrrolidone, and then dimethicone, cyclodimethicone, dimethicone copolyol crosspolymer dimethicone, polyethylene glycol, stearic acid were added to prepare a drug layer solution on the gel.

The adhesive layer added silicone to heptane or ethyl acetate solution to prepare an adhesive layer solution on the gel.

The back layer was used by purchasing a silicon matrix manufactured by Dow Corning Corporation.

The adhesive layer solution was added to the back layer, and cast and dried. Next, the drug layer was cast and dried to prepare a whitening patch.

Example  2

Slimming patches were prepared with the following composition:

(1) drug layer preparation solution

Lipoic acid 3%

Theophylline 2%

Kakaoji 85%

Polyethylene glycol 3%

Purified water was added to make 100%.

(2) Adhesive layer manufacturing solution

Polyacrylate 22%

Ethanol 78%

(3) back layer manufacturing solution

Ethyl cellulose 25%

Glycerin 5%

Ethanol 70%

Lipoic acid and theophylline were dissolved in cacao butter, polyethylene glycol, and purified water to prepare a disk-type drug layer.

The back layer was prepared by melting ethyl cellulose and glycerin in ethanol and casting the film, and the adhesive layer was prepared by casting polyacrylate dissolved in ethanol on the back layer. Thereafter, the drug layer was laminated on the adhesive layer to prepare a slimming patch.

Example  3

Atopy improvement patches were prepared with the following composition:

(1) drug layer preparation solution

Catechin 2%

Dimethicone 6%

Cyclodimethicone 2%

Dimethicone Copolyol Crosspolymer Dimethicone 8%

Propylene Glycol 1%

Cabopol 1%

DMSO 0.01%

Purified water was added to make 100%.

The catechin was dissolved in purified water and added to Carbopol and then increased. Then, a dimethicone, cyclodimethicone, dimethicone copolyol crosspolymer dimethicone, propylene glycol, DMSO was added to prepare a drug layer on the gel.

The back layer was obtained by using a urethane film, and the adhesive layer was cast by Dow Corning Co., Ltd. on a polyester coated with a fluorinated hydrocarbon-like material or manufactured by hot melting, and then laminated by two layers. It was.

An atopic improvement patch was prepared by casting a drug layer on the gel onto the laminated semifinished product.

Comparative example  1 to 3

The drug solutions of Comparative Examples 1 to 3 were prepared according to the prescription of Table 1, and each drug solution was cast on the back layer and the adhesive layer of Examples 1 to 3, and a known adhesive dispersion type (adhesive dispersion type); Patches of the drug matrix were not liquefied). For effective comparison, the thickness of the drug layer and the content of each drug were adjusted to be the same as in the Examples and Comparative Examples.

Ingredient (% by weight) Comparative Example 1 Comparative Example 2 Comparative Example 3 Polyvinyl pyrrolidone 17 17 17 Polyethylene glycol 2 2 2 glycerin 3 3 3 Stearic acid 0.1 0.1 0.1 Arbutin One - - Lipoic acid - 3 - Theophylline - 2 - Catechin - - 2

Effect Test Example 1 Evaluation of Absorption Rate

Hairless mouse skin, human cadaver skin was immobilized on Franz cells at 36.5 ° C. and then the formulations of Examples 2 and 3, Comparative Examples 2 and 3 were applied to the donor department, Receptor solutions were filled with HEPES buffered saline (pH 7.4) and sampled for 0, 5, 15, 30, 60, 120 and 240 minutes. The obtained sample was analyzed using LC Mass. The analyzed data was used to calculate the dissolution rate per unit area of drug. However, in the case of Example 2 and Comparative Example 2, the absorption rate of theophylline was calculated. Table 2 shows the results.

Skin Penetration Rate (mg / cm ² / hr) Hairless mouse Human corpse Example 2 0.25 0.18 Example 3 0.14 0.15 Comparative Example 2 0.05 0.03 Comparative Example 3 0.07 0.06

As shown in Table 2, the patches of Examples 2 and 3 was found to have a higher absorption rate than the patches of Comparative Examples 2 and 3. This indicates that the patch according to the present invention, in which the matrix is liquefied by friction or body temperature, has a faster absorption rate than conventionally known patches.

Effect Test Example 2 : Whitening Effect on Human Skin

Twenty healthy men were attached with an opaque tape with 6 holes of 1.5 cm in diameter on the back of the subject, and then irradiated with 1.5 ~ 2 times of ultraviolet light (UVB) to the minimum amount of erythema of each subject. Induced. Next, the patches of Example 1 and Comparative Example 1 were attached to the skin once a day for 4 hours, and after 1 week, 2 weeks and 4 weeks, the contrast of the skin was measured using a chromameter. The determination of the effect was determined by obtaining an L value representing the contrast of the skin. The results are shown in Table 3 below.

Brightness change after 1 week Brightness change after 2 weeks Brightness change after 3 weeks Example 1 0.82 ± 0.12 1.7 ± 0.77 2.55 ± 0.98 Comparative Example 1 0.21 ± 0.1 0.52 ± 0.4 0.78 ± 0.35

As shown in Table 3, the patch of Example 1 showed a higher whitening effect than the patch of Comparative Example 1. This is believed to be due to the liquefaction of the matrix of the drug layer in the patch of Example 1 causing rapid whitening effect expression.

As described above, in the patch of the present invention, the drug layer or drug-adhesive composite layer containing the drug is liquefied by body temperature or friction, so that the permeability to the skin is high, so that the rapid absorption of the drug and the rapid effect accordingly Expression is possible and convenient to use. Therefore, when used as a skin care patch can exhibit a rapid whitening, wrinkle improvement, slimming, anti-aging, atopy improvement.

Claims (14)

A patch-like preparation for adhering to skin, comprising: a backing layer, an adhesive layer, a skin care patch comprising a skin care ingredient and a drug layer and a release liner liquefied by body temperature and friction, In the drug layer, suppository bases including cacao butter, glycerogelatin, Witepsol and laurin paper as bases liquefied by body temperature, cetyl ester waxes, microcrystalline waxes, non-emulsifying ( waxes including non-emulsifying waxes, white waxes and yellow waxes, poloxamers, derivatives of poly (N-isopropylacrylamide) (Poly (N-isopropylacrylamide)), Bases consisting of derivatives of poly (N-cyclopropylmethacrylamide), copolymers of diacetone acrylamide and hydroxyethyl acrylate, or mixtures thereof ; Or a base composed of dimethicone, cyclomethicone or a copolymer having a basic structure thereof, dimethicone copolyol crosspolymer dimethicone, or a mixture thereof as a base liquefied by friction. Skin beauty patch. What is claimed is: 1. A patch-type preparation adhered to the skin, comprising: a backing layer, a skin care patch comprising a skin care ingredient and a drug-adhesive composite layer and a release liner, which are liquefied by body temperature and friction, In the drug layer, suppository bases including cacao butter, glycerogelatin, Witepsol and laurin paper as bases liquefied by body temperature, cetyl ester waxes, microcrystalline waxes, non-emulsifying ( waxes including non-emulsifying waxes, white waxes and yellow waxes, poloxamers, derivatives of poly (N-isopropylacrylamide) (Poly (N-isopropylacrylamide)), Bases consisting of derivatives of poly (N-cyclopropylmethacrylamide), copolymers of diacetone acrylamide and hydroxyethyl acrylate, or mixtures thereof ; Or a base composed of dimethicone, cyclomethicone or a copolymer having a basic structure thereof, dimethicone copolyol crosspolymer dimethicone, or a mixture thereof as a base liquefied by friction. Skin beauty patch. delete delete The method of claim 1 or 2, wherein the material used as the back layer is polyvinyl acetate, ethyl cellulose, poly methyl methacrylate, methacryloyl ethyl betaine / methacylate copolymer. ), Methacrylic acid copolymers, aminoalkyl methacrylate copolymers, cellulose acetate phthalates, polyvinylpyrrolidone / vinyl acetate copolymers, hydride Hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropylethyl cellulose, polyethylene terephthalate, polyethylene, polypropylene, polyvinyl chloride Silicone sheet A cosmetic patch for skin, characterized in that it is a matrix, a urethane matrix, a rubber, a metal foil, a polymer-metal composition, a fabric, or a mixture thereof. The adhesive used in the adhesive layer according to claim 1 or 2, wherein the adhesive used in the adhesive layer is silicone containing polydimethylsiloxane, acrylic adhesive containing polyacrylate, polyisobutylene adhesive, or mixtures thereof. It is a skin beauty patch agent. The skin care patch according to claim 1 or 2, wherein the release liner is polyester coated with silicone or hydrocarbon added with fluorine. A hydrocarbon, ethanol, methanol and lauryl alcohol, comprising alkanes and alkenes of 9 to 22 carbon atoms as claimed in claim 1. Alcohols, including polyethylene glycol, polyols including propylene glycol, lauric acid, myristic acid, stearic acid and oleic acid Fatty acids and derivatives, including glyceryl monolaurate, glyceryl monooleate, glyceryl monocaprylate, ethyloleate and ethyldecanoate esters containing ethyldecanoate, N, N-dimethylamino acetate and 1- (N, N-dimethylamino) -2-propanol decanoate (1- (N, N-dimethylamino) ) -2-propanol alkyl amino esters including decanoate, amides including Azone®, dimethylformamide and demethylacetamide, PEG2 oleamine, phenethylamine ( amines including phenethylamine, stearylamine, triethylamine and dodecylamine and salts thereof, carvacrol, thymol and anethole Aromatic compounds, including; and sulfoxides, including n-decylmethyl sulfoxide, cyclodextrins, including β-CD and HP-β-CD, α- Terpenes, including terpene, p-menthane, d-limonene, dipentene and menthol, N-methyl-pyrrolidone ; NMP), pyrrolidone, imidazole derivatives, or mixtures thereof, including 1-ethyl pyrrolidone and 1-butyl pyrrolidone. Skin cosmetic patch, characterized in that it further comprises. 9. The skin care patch of claim 8, wherein the absorption accelerator is 0.001 to 10% by weight based on the weight of the drug layer. The skin cosmetic patch for skin whitening according to claim 1 or 2, wherein the skin cosmetic ingredient comprises arbutin in an amount ranging from 0.001 to 30% by weight based on the weight of the drug layer. The skin cosmetic patch for atopy improvement according to claim 1 or 2, comprising catechin in a range of 0.001 to 30% by weight based on the weight of the drug layer. delete delete The method of claim 1 or 2, wherein the skin cosmetic ingredients include lipoic acid (lipoic acid), theophylline (theophylline), or a mixture thereof in the range of 0.001 to 30% by weight based on the weight of the drug layer for slimming Skin Beauty Patches.

Images